vs

Side-by-side financial comparison of Alignment Healthcare, Inc. (ALHC) and CLOVER HEALTH INVESTMENTS, CORP. (CLOV). Click either name above to swap in a different company.

Alignment Healthcare, Inc. is the larger business by last-quarter revenue ($1.0B vs $487.7M, roughly 2.1× CLOVER HEALTH INVESTMENTS, CORP.). Alignment Healthcare, Inc. runs the higher net margin — -1.1% vs -10.1%, a 9.0% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 44.4%). Alignment Healthcare, Inc. produced more free cash flow last quarter ($-55.4M vs $-68.7M). Over the past eight quarters, Alignment Healthcare, Inc.'s revenue compounded faster (26.9% CAGR vs 18.6%).

Alignment Healthcare, Inc. is a U.S.-based healthcare provider offering Medicare Advantage plans for seniors. It adopts a value-based care model, partnering with local providers to deliver personalized coordinated medical services, prescription drug coverage and supplemental benefits to members across multiple U.S. states.

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

ALHC vs CLOV — Head-to-Head

Bigger by revenue
ALHC
ALHC
2.1× larger
ALHC
$1.0B
$487.7M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+0.3% gap
CLOV
44.7%
44.4%
ALHC
Higher net margin
ALHC
ALHC
9.0% more per $
ALHC
-1.1%
-10.1%
CLOV
More free cash flow
ALHC
ALHC
$13.3M more FCF
ALHC
$-55.4M
$-68.7M
CLOV
Faster 2-yr revenue CAGR
ALHC
ALHC
Annualised
ALHC
26.9%
18.6%
CLOV

Income Statement — Q4 2025 vs Q4 2025

Metric
ALHC
ALHC
CLOV
CLOV
Revenue
$1.0B
$487.7M
Net Profit
$-11.0M
$-49.3M
Gross Margin
Operating Margin
-1.0%
-10.1%
Net Margin
-1.1%
-10.1%
Revenue YoY
44.4%
44.7%
Net Profit YoY
64.6%
-123.2%
EPS (diluted)
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALHC
ALHC
CLOV
CLOV
Q4 25
$1.0B
$487.7M
Q3 25
$993.7M
$496.6M
Q2 25
$1.0B
$477.6M
Q1 25
$926.9M
$462.3M
Q4 24
$701.2M
$337.0M
Q3 24
$692.4M
$331.0M
Q2 24
$681.3M
$356.3M
Q1 24
$628.6M
$346.9M
Net Profit
ALHC
ALHC
CLOV
CLOV
Q4 25
$-11.0M
$-49.3M
Q3 25
$3.7M
$-24.4M
Q2 25
$15.7M
$-10.6M
Q1 25
$-9.1M
$-1.3M
Q4 24
$-31.1M
$-22.1M
Q3 24
$-26.4M
$-9.2M
Q2 24
$-24.0M
$7.4M
Q1 24
$-46.5M
$-19.2M
Gross Margin
ALHC
ALHC
CLOV
CLOV
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
24.5%
Q2 24
30.3%
Q1 24
23.6%
Operating Margin
ALHC
ALHC
CLOV
CLOV
Q4 25
-1.0%
-10.1%
Q3 25
0.8%
-4.9%
Q2 25
2.2%
-2.2%
Q1 25
-0.6%
-0.3%
Q4 24
-3.2%
-6.4%
Q3 24
-2.8%
-2.7%
Q2 24
-2.7%
2.0%
Q1 24
-6.5%
-6.5%
Net Margin
ALHC
ALHC
CLOV
CLOV
Q4 25
-1.1%
-10.1%
Q3 25
0.4%
-4.9%
Q2 25
1.5%
-2.2%
Q1 25
-1.0%
-0.3%
Q4 24
-4.4%
-6.6%
Q3 24
-3.8%
-2.8%
Q2 24
-3.5%
2.1%
Q1 24
-7.4%
-5.5%
EPS (diluted)
ALHC
ALHC
CLOV
CLOV
Q4 25
$-0.04
Q3 25
$0.02
Q2 25
$0.07
Q1 25
$-0.05
Q4 24
$-0.15
Q3 24
$-0.14
Q2 24
$-0.13
Q1 24
$-0.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALHC
ALHC
CLOV
CLOV
Cash + ST InvestmentsLiquidity on hand
$604.2M
$78.3M
Total DebtLower is stronger
$323.2M
Stockholders' EquityBook value
$179.3M
$308.7M
Total Assets
$1.1B
$541.0M
Debt / EquityLower = less leverage
1.80×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALHC
ALHC
CLOV
CLOV
Q4 25
$604.2M
$78.3M
Q3 25
$644.1M
Q2 25
$503.8M
Q1 25
$479.5M
Q4 24
$470.6M
$194.5M
Q3 24
$381.0M
$288.0M
Q2 24
$363.7M
$254.8M
Q1 24
$301.7M
$208.3M
Total Debt
ALHC
ALHC
CLOV
CLOV
Q4 25
$323.2M
Q3 25
$322.7M
Q2 25
$322.3M
Q1 25
$321.9M
Q4 24
$321.4M
Q3 24
$212.0M
Q2 24
$211.7M
Q1 24
$162.0M
Stockholders' Equity
ALHC
ALHC
CLOV
CLOV
Q4 25
$179.3M
$308.7M
Q3 25
$161.9M
$340.9M
Q2 25
$141.0M
$344.2M
Q1 25
$108.1M
$336.1M
Q4 24
$99.9M
$341.1M
Q3 24
$114.5M
$342.2M
Q2 24
$123.7M
$324.9M
Q1 24
$130.9M
$292.5M
Total Assets
ALHC
ALHC
CLOV
CLOV
Q4 25
$1.1B
$541.0M
Q3 25
$1.1B
$559.7M
Q2 25
$1.0B
$575.0M
Q1 25
$895.6M
$583.7M
Q4 24
$782.1M
$580.7M
Q3 24
$692.3M
$653.0M
Q2 24
$716.3M
$674.2M
Q1 24
$633.2M
$671.8M
Debt / Equity
ALHC
ALHC
CLOV
CLOV
Q4 25
1.80×
Q3 25
1.99×
Q2 25
2.29×
Q1 25
2.98×
Q4 24
3.22×
Q3 24
1.85×
Q2 24
1.71×
Q1 24
1.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALHC
ALHC
CLOV
CLOV
Operating Cash FlowLast quarter
$-50.4M
$-68.2M
Free Cash FlowOCF − Capex
$-55.4M
$-68.7M
FCF MarginFCF / Revenue
-5.5%
-14.1%
Capex IntensityCapex / Revenue
0.5%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$113.1M
$-69.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALHC
ALHC
CLOV
CLOV
Q4 25
$-50.4M
$-68.2M
Q3 25
$144.6M
$12.1M
Q2 25
$29.1M
$5.4M
Q1 25
$16.6M
$-16.3M
Q4 24
$-8.7M
$-85.8M
Q3 24
$26.2M
$50.0M
Q2 24
$23.5M
$44.8M
Q1 24
$-6.2M
$25.9M
Free Cash Flow
ALHC
ALHC
CLOV
CLOV
Q4 25
$-55.4M
$-68.7M
Q3 25
$139.1M
$11.4M
Q2 25
$21.1M
$4.8M
Q1 25
$8.4M
$-16.5M
Q4 24
$-18.0M
$-86.1M
Q3 24
$16.9M
$49.6M
Q2 24
$11.8M
$44.4M
Q1 24
$-17.4M
$25.5M
FCF Margin
ALHC
ALHC
CLOV
CLOV
Q4 25
-5.5%
-14.1%
Q3 25
14.0%
2.3%
Q2 25
2.1%
1.0%
Q1 25
0.9%
-3.6%
Q4 24
-2.6%
-25.6%
Q3 24
2.4%
15.0%
Q2 24
1.7%
12.5%
Q1 24
-2.8%
7.3%
Capex Intensity
ALHC
ALHC
CLOV
CLOV
Q4 25
0.5%
0.1%
Q3 25
0.6%
0.1%
Q2 25
0.8%
0.1%
Q1 25
0.9%
0.0%
Q4 24
1.3%
0.1%
Q3 24
1.3%
0.1%
Q2 24
1.7%
0.1%
Q1 24
1.8%
0.1%
Cash Conversion
ALHC
ALHC
CLOV
CLOV
Q4 25
Q3 25
38.77×
Q2 25
1.86×
Q1 25
Q4 24
Q3 24
Q2 24
6.04×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons